Solriamfetol

DRUG9 trials

Conditions

ADHDBinge Eating DisorderBinge-Eating DisorderExcessive Daytime SleepinessHypersomniaIdiopathic HypersomniaImpaired Cognitive FunctionLong COVID

Phase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

RecruitingNCT06170970

Johns Hopkins UniversityMultiple Sclerosis, Multiple Sclerosis Fatigue

Start: 2024-06-01End: 2027-03-01Target: 46Updated: 2026-06-09

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

CompletedNCT06404099

Duke UniversityHypersomnia, Long COVID, Long COVID-19

Start: 2024-08-12End: 2026-04-20Updated: 2026-06-03

RECOVER-SLEEP: Platform Protocol

CompletedNCT06404086

Duke UniversityHypersomnia, Long COVID, Long COVID-19 +1

Start: 2024-07-31End: 2025-12-31Updated: 2026-01-22

Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.

Not yet recruitingNCT06590662

University Hospital, MontpellierIdiopathic Hypersomnia

Start: 2024-09-15End: 2027-06-01Target: 60Updated: 2024-09-19

Phase 3

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

CompletedNCT06103825

Ignis Therapeutics (Suzhou) LimitedExcessive Daytime Sleepiness, Sleep Apnea, Obstructive

Start: 2023-08-01End: 2024-08-19Updated: 2025-03-03

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

Enrolling by invitationNCT06878976

Axsome Therapeutics, Inc.Binge-Eating Disorder

Start: 2025-02-20End: 2027-12-01Target: 236Updated: 2026-08-11

An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

Enrolling by invitationNCT07773883

Axsome Therapeutics, Inc.ADHD

Start: 2026-08-06End: 2027-12-01Target: 300Updated: 2026-09-08

Phase 4

Solriamfetol in Binge Eating Disorder

NCT04602936

Lindner Center of HOPEBinge Eating Disorder

Start: 2021-06-15End: 2024-12-30Target: 64Updated: 2023-03-08

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

CompletedNCT04789174

Axsome Therapeutics, Inc.Excessive Daytime Sleepiness, Impaired Cognitive Function, Obstructive Sleep Apnea

Start: 2021-05-17End: 2022-09-19Updated: 2026-01-26

Related Papers

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

2025-10-23

Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP): A Randomized Placebo-Controlled Double-Blind Repeated-Measures Crossover Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment.

2024-11-092 citations

0762 Baseline characteristics: Solriamfetol’s effect on cognitive Health in Apnea participants during a Randomized Placebo-controlled study (SHARP)

SLEEP2022-05-251 citations

Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder.

2021-10-022 citations